Pathology: breast cancer - adjuvant; la/mBC - HR positive; la/mBC - HR-positive - 1st line (L1); la/mBC - HR-positive - 2nd line (L2);
breast cancer - adjuvant | la/mBC - HR positive | la/mBC - HR-positive - 1st line (L1) | la/mBC - HR-positive - 2nd line (L2) | ||||||
PALLAS, 2022 | PENELOPE-B, 2021 | KCSG-BR15-10, 2019 | PENELOPE-B, 2021 | PALOMA-1, 2016 | PALOMA-2, 2016 | PALOMA-3, 2016 | FLIPPER, 2021 | ||
palbociclib plus endocrine therapy | 3 | T1 | T1 | T1 | |||||
palbociclib plus fulvestrant | 2 | T1 | T1 | ||||||
palbociclib plus letrozole | 2 | T1 | T1 | ||||||
palbociclib | 1 | T1 | |||||||
endocrine therapy | 0 | T0 | T0 | T0 | |||||
capecitabine | 0 | T0 | |||||||
fulvestrant | 0 | T0 | T0 | ||||||
letrozole | 0 | T0 | T0 |